210P Real-world outcomes in patients (pts) with HR+/HER2– metastatic breast cancer (mBC) and germline/tumour BRCA mutations (g/tBRCA1/2m) receiving 1st-line (1L) CDK4/6i plus endocrine therapy (ET)
- Resource Type
- Abstract
- Source
- In
ESMO Open May 2023 8(1) Supplement 4 - Subject
- Language
- ISSN
- 2059-7029